By Nandu Deorkar, Ph.D., MBA, Senior Vice President, Research & Development — Biopharma Production, Avantor
Today monoclonal antibodies (mAbs) represent the largest sector of the biopharmaceutical market. This brings about concerns for the costs of downstream processing, which accounts for roughly 60 percent of the cost of producing a biologic drug and often takes place over a period of week. Of downstream processes, buffer management and chromatographic purification operations are the primary areas being reconsidered for an innovative upgrade.
Find out where these two areas are currently showing inefficiencies, and explore data-driven solutions in areas where there is room for change and enhancements.